Bioprocess Technology Market to record USD 55.84 Bn growth -- Evolving Opportunities with Advanced Instruments LLC and Becton Dickinson and Co.
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- The "Bioprocess Technology Market by End-user and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The report expects the market size to grow by USD 55.84 billion between 2021 and 2026, expanding at a CAGR of 12.27% during the forecast period. The report considered various aspects such as the consumer base, adoption rate, average selling price, revenue generated by vendors, and various other factors to estimate the market size. Download Sample Report Here
The market is driven by the increase in infectious diseases. In addition, increasing clinical trials in countries is anticipated to boost the growth of the bioprocess technology market.
The prevalence of infectious diseases is increasing at a faster rate due to the growing global population. In addition, the rapid spread of global pandemics such as Ebola, SARS, swine flu, Zika, and Lassa fever created high demand for vaccines and drugs to treat the cause. This led to the R&D of antiviral drugs, cell-based therapies, and vaccines using cell culture methods. For instance, in July 2021, Cytiva and Pall Corp. announced its capacity expansion plan to increase the manufacture of key products used to make biologic medicines. New sites are opening in the US and the UK to address regional manufacturing models. Many such investments are expected to drive the growth of the global bioprocess technology market during the forecast period.
Vendor Landscape:
The global bioprocess technology market is fragmented due to the presence of several well-established players. Major players are focusing on investing in R&D to develop new products. Vendors are also involved in M&A to gain a competitive edge in the market. The immense growth opportunities in the market, which include the application of bioprocess biotechnology, will increase competition among vendors.
Technavio identifies the following as the key players in the market:
Advanced Instruments LLC
Becton Dickinson and Co.
Boehringer Ingelheim International GmbH
Catalent Inc.
Charles River Laboratories International Inc.
Corning Inc.
Dover Corp.
Emerson Electric Co.
Fujifilm Diosynth Biotechnologies USA Inc.
General Electric Co.
Koninklijke Philips NV
Lonza Group Ltd.
Merck KGaA
Nova Biomedical Corp.
Repligen Corp.
Sartorius AG
STADA Arzneimittel AG
Thermo Fisher Scientific Inc.
Univercells SA
Eppendorf AG
The report segments the global bioprocess technology market by end-user (biopharmaceutical companies, contract manufacturing organizations, academic research institutes, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Bioprocess Technology Market End-user Outlook (Revenue, USD bn, 2021-2026)
Biopharmaceutical companies - size and forecast 2021-2026
Contract manufacturing organizations - size and forecast 2021-2026
Academic research institute - size and forecast 2021-2026
Others - size and forecast 2021-2026
Bioprocess Technology Market Geography Outlook (Revenue, USD bn, 2021-2026)
North America - size and forecast 2021-2026
Europe - size and forecast 2021-2026
Asia - size and forecast 2021-2026
Rest of World (ROW) - size and forecast 2021-2026
Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request Sample Report Here
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 42%
Key consumer countries
US, Germany, UK, France, and China
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
Advanced Instruments LLC, Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Catalent Inc., Charles River Laboratories International Inc., Corning Inc., Dover Corp., Emerson Electric Co., Fujifilm Diosynth Biotechnologies USA Inc., General Electric Co., Koninklijke Philips NV, Lonza Group Ltd., Merck KGaA, Nova Biomedical Corp., Repligen Corp., Sartorius AG, STADA Arzneimittel AG, Thermo Fisher Scientific Inc., Univercells SA, and Eppendorf AG
Market Dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of Contents:
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary ? Chart on Market Overview
Exhibit 02: Executive Summary ? Data Table on Market Overview
Exhibit 03: Executive Summary ? Chart on Global Market Characteristics
Exhibit 04: Executive Summary ? Chart on Market by Geography
Exhibit 05: Executive Summary ? Chart on Market Segmentation by End-user
Exhibit 06: Executive Summary ? Chart on Incremental Growth
Exhibit 07: Executive Summary ? Data Table on Incremental Growth
Exhibit 08: Executive Summary ? Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ billion)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ billion)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers ? Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers ? Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants ? Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes ? Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry ? Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by End-user
5.1 Market segments
Exhibit 24: Chart on End-user - Market share 2021-2026 (%)
Exhibit 25: Data Table on End-user - Market share 2021-2026 (%)
5.2 Comparison by End-user
Exhibit 26: Chart on Comparison by End-user
Exhibit 27: Data Table on Comparison by End-user
5.3 Biopharmaceutical companies - Market size and forecast 2021-2026
Exhibit 28: Chart on Biopharmaceutical companies - Market size and forecast 2021-2026 ($ billion)
Exhibit 29: Data Table on Biopharmaceutical companies - Market size and forecast 2021-2026 ($ billion)
Exhibit 96: Boehringer Ingelheim International GmbH - Overview
Exhibit 97: Boehringer Ingelheim International GmbH - Business segments
Exhibit 98: Boehringer Ingelheim International GmbH - Key news
Exhibit 99: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 100: Boehringer Ingelheim International GmbH - Segment focus
10.5 Eppendorf AG
Exhibit 101: Eppendorf AG - Overview
Exhibit 102: Eppendorf AG - Product / Service
Exhibit 103: Eppendorf AG - Key news
Exhibit 104: Eppendorf AG - Key offerings
10.6 Lonza Group Ltd.
Exhibit 105: Lonza Group Ltd. - Overview
Exhibit 106: Lonza Group Ltd. - Business segments
Exhibit 107: Lonza Group Ltd. - Key news
Exhibit 108: Lonza Group Ltd. - Key offerings
Exhibit 109: Lonza Group Ltd. - Segment focus
10.7 Merck KGaA
Exhibit 110: Merck KGaA - Overview
Exhibit 111: Merck KGaA - Business segments
Exhibit 112: Merck KGaA - Key news
Exhibit 113: Merck KGaA - Key offerings
Exhibit 114: Merck KGaA - Segment focus
10.8 Nova Biomedical Corp.
Exhibit 115: Nova Biomedical Corp. - Overview
Exhibit 116: Nova Biomedical Corp. - Product / Service
Exhibit 117: Nova Biomedical Corp. - Key offerings
10.9 Repligen Corp.
Exhibit 118: Repligen Corp. - Overview
Exhibit 119: Repligen Corp. - Product / Service
Exhibit 120: Repligen Corp. - Key news
Exhibit 121: Repligen Corp. - Key offerings
10.10 Sartorius AG
Exhibit 122: Sartorius AG - Overview
Exhibit 123: Sartorius AG - Business segments
Exhibit 124: Sartorius AG - Key news
Exhibit 125: Sartorius AG - Key offerings
Exhibit 126: Sartorius AG - Segment focus
10.11 Thermo Fisher Scientific Inc.
Exhibit 127: Thermo Fisher Scientific Inc. - Overview
Exhibit 128: Thermo Fisher Scientific Inc. - Business segments
Exhibit 129: Thermo Fisher Scientific Inc. - Key news
Exhibit 130: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 131: Thermo Fisher Scientific Inc. - Segment focus
10.12 Univercells SA
Exhibit 132: Univercells SA - Overview
Exhibit 133: Univercells SA - Product / Service
Exhibit 134: Univercells SA - Key offerings
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 135: Inclusions checklist
Exhibit 136: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 137: Currency conversion rates for US$
11.4 Research methodology
Exhibit 138: Research methodology
Exhibit 139: Validation techniques employed for market sizing
Exhibit 140: Information sources
11.5 List of abbreviations
Exhibit 141: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...
Emmy-winning actor and St. Louis native Jon Hamm took the stage Saturday, May 18, to offer words of wisdom to the newest graduates of Saint Louis University (SLU) during the University's spring commencement in St. Louis. ...
Nearly 900 undergraduates of the Class of 2024 celebrated their send-off from Bentley University in a very different way than their 2020 arrival amid the COVID-19 pandemic. The 105th undergraduate commencement ceremony was marked by maskless smiles,...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...